CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$50.71
-2.59% today
Updated 2026-04-29
Market cap
$4.70B
P/E ratio
—
P/S ratio
1,340.31x
EPS (TTM)
$-6.47
Dividend yield
—
52W range
$33 – $78
Volume
2.0M
Crispr Therapeutics AG (CRSP) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-17,912.00%
ROE
-30.20%
ROA
-15.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2014 | $0.00 | $-6.80M | — | — | — |
| 2015 | $247000.00 | $-25.83M | -4,990.28% | -10,416.60% | -10,456.68% |
| 2016 | $5.16M | $-23.20M | -717.93% | -1,319.33% | -449.30% |
| 2017 | $41.00M | $-68.36M | -70.26% | -157.69% | -166.74% |
| 2018 | $3.12M | $-164.98M | 100.00% | -5,087.80% | -5,281.08% |
| 2019 | $289.59M | $66.86M | 100.00% | 16.14% | 23.09% |
| 2020 | $719000.00 | $-348.87M | -37,369.68% | -49,295.55% | -48,520.86% |
| 2021 | $913.08M | $377.66M | 100.00% | 40.91% | 41.36% |
| 2022 | $436000.00 | $-650.17M | -25,186.70% | -154,394.72% | -149,122.71% |
| 2023 | $370.00M | $-153.61M | 64.80% | -60.15% | -41.52% |
| 2024 | $35.00M | $-366.25M | -215.00% | -1,333.05% | -1,046.43% |
| 2025 | $3.51M | $-581.60M | -6,537.01% | -16,191.40% | -16,569.77% |